Introduction
============

Gastric cancer (GC) remains one of the leading causes of cancer-related mortality worldwide.[@b1-cmar-9-539] Although great improvements have been made in the treatment of GC, five-year survival rates have remained very low, approximating 20%, due to the tendency for early invasion and metastasis.[@b2-cmar-9-539] Clinically, TNM stage is predominantly used to predict the outcome of GC patients. However, growing evidence has suggested that patients with the same stage might have vastly different prognoses due to the heterogeneity of tumors.[@b3-cmar-9-539],[@b4-cmar-9-539] Therefore, it is urgent to find useful biomarkers to refine risk stratification and survival prognosis.

Eukaryotic initiation factor 3 (eIF3) is a protein complex involved in the initiation pathway. Functional eIF3 binds to the 40S ribosomal subunit and promotes the formation of the 40S initiation complex.[@b6-cmar-9-539],[@b7-cmar-9-539] It has been shown that eIF3 is the largest initiation factor composed of 13 non-identical subunits denoted as eIF3a-m.[@b5-cmar-9-539]--[@b7-cmar-9-539] Several eIF3 subunits, such as eIF3a, eIF3b, eIF3c, eIF3h, eIF3i, and eIF3e, have been demonstrated to promote cell proliferation by initiating protein translation in cancers.[@b8-cmar-9-539] In addition, eIF3f subunit has been shown to be downregulated in cancers.[@b9-cmar-9-539] Recent studies have reported that deregulation of eIF3 subunits is implicated in tumorigenesis.[@b10-cmar-9-539]--[@b12-cmar-9-539]

The eIF3 subunit d (eIF3d), categorized as the largest subunit of eIF3, is crucial for the functional activity of eIF3.[@b13-cmar-9-539],[@b14-cmar-9-539] Recent studies have reported eIF3d over expression in several malignant tumors, including prostate cancer,[@b15-cmar-9-539] colon cancer,[@b16-cmar-9-539] and melanoma.[@b17-cmar-9-539] The eIF3d has also been identified as a potential therapeutic target in several cancer types.[@b17-cmar-9-539]--[@b19-cmar-9-539] Similarly, Kim et al identified eIF3d as a predictive gene in GC. This information might be useful in establishing resistance against a combined treatment of cisplatin and fluorouracil.[@b20-cmar-9-539]

The expression of eIF3d in human GC tissue and its clinical significance have not been reported in the literature. In this study, we analyzed eIF3d expression in primary GC from 210 Chinese patients by immunohistochemical analysis and investigated the relationship of eIF3d and various clinicopathological factors.

Patients and methods
====================

Specimen source and patient information
---------------------------------------

A total of 210 patients with GC who had received curative gastrectomy in the Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China, between January 2006 and October 2010 were enrolled in this study. Patients, age ranged from 22 to 87 years (mean age, 59.6 years). The mean follow-up period was 40.96 months with a range from 2 to 89 months. The TNM stage of tumors was evaluated according to the 7th edition of the TNM Classification of GC.[@b22-cmar-9-539] No patient underwent radiotherapy or chemotherapy before surgery. The 210 GC tissues and 195 adjacent noncancerous (ANC) tissues were obtained from these specimens for immunohistochemical staining. All these specimens were fixed with 10% formaldehyde and embedded with paraffin, and were examined by a pathologist to confirm malignancy. The above cases were approved by the ethics committee of Huadong Hospital and informed consent forms were signed.

Immunostaining analysis
-----------------------

A polyclonal antibody against eIF3d (ab155419; Abcam, Cambridge, MA, USA) was used in this study. Specimens were sectioned into 3- to 4-μm slices. After routine xylene dewaxing and gradient ethanol hydration, the slides were blocked with 3% hydrogen peroxide for 10 min. After using the microwave antigen repair method, the slides were incubated with the anti-eIF3d Ab (diluted 1:40 in phosphate buffered saline \[PBS\]) at 4°C for 24 h. Sections were washed thrice with PBS, followed by the addition of diaminobenzidine for 6 min. Slides were independently evaluated by two pathologists who were blinded to clinical data. The level of eIF3d was scored not only by staining intensity but also by the percentage of cells that exhibit eIF3d. The staining intensity was scored as 0 (no staining), 1 (weak), 2 (moderate), or 3 (intense staining). The percentage of positive cells was scored as follows: 0 (≤5%), 1 (6% to 25%), 2 (26% to 50%), and 3 (\>50%). The total of the above two scores was graded as follows: 0 (score 0), 1 (score 1--2), 2 (score 3--4), and 3 (score 5--6), where the total scores of 0 or 1 were designated as low expression and 2 or 3 were designated as high expression.[@b21-cmar-9-539]

Statistical analysis
--------------------

The SPSS 19 software package (IBM Corporation, Armonk, NY, USA) was used for statistical analysis. Student's *t*-test was used for continuous variables, whereas *c*^2^ test or Fisher's exact test was used for proportions. The Kaplan--Meier method was used for survival analyses and the Cox regression model was used for prognostic factors, such as eIF3d and other clinicopathological features.

Results
=======

Expression of eIF3d in GC tissues
---------------------------------

The eIF3d staining results predominantly showed cytoplasmic staining in both the GC tissues and the ANC tissues ([Figure 1](#f1-cmar-9-539){ref-type="fig"}). However, a sharp difference was found when eIF3d expression in GC was compared with that of ANC. The high eIF3d expression rate in GC tissues was 45.2% (95/210) while that in ANC tissues was 21.0% (41/195; *p*\<0.001).

eIF3d expression and clinicopathological features
-------------------------------------------------

Expression of eIF3d (high expression in 95 patients; low expression in 115 patients) and clinicopathological features were analyzed. [Table 1](#t1-cmar-9-539){ref-type="table"} summarizes the positive correlates of upregulated eIF3d expression with lymph node metastasis (*p*=0.041), tumor depth (*p*=0.007), and late TNM stage (III/IV) (*p*=0.027). The data indicate that eIF3d did not correlate significantly with gender (*p*=0.217), age (*p*=0.724), primary tumor location (*p*=0.403), or lymphovascular invasion (*p*=0.312).

eIF3d as a predictor of overall survival in GC patients
-------------------------------------------------------

Kaplan--Meier survival curves showed that the cumulative survival rates were 75.6% (3 years) and 72.9% (5 years) in patients with lower eIF3d expression, and 59.5% (3 years) and 52.9% (5 years) in those with higher eIF3d expression. The overexpression of eIF3d was significantly correlated with poor overall survival of GC patients (*p*=0.005). The data were divided into subgroups according to the TNM stage. The 5-year survival rates were 97.6% and 95.8% in low and high eIF3d patients, respectively (*p*=0.925) in stage I and 75.6% and 58.6%, respectively (*p*=0.274) in stage II. However, in stage III, the 5-year survival rate in low eIF3d patients was significantly higher than that of high eIF3d patients (52.4% vs. 29.7%, *p*=0.046; [Figure 2](#f2-cmar-9-539){ref-type="fig"}). Furthermore, multivariate survival analysis was performed using the Cox multivariate regression model. The results revealed that eIF3d levels (HR=1.804; 95% CI: 1.112--2.926; *p*=0.017), lymph nodes metastasis (HR=3.082; 95% CI: 1.101--8.629; *p*=0.032), distant metastasis (HR=3.776; 95% CI: 1.362--10.464; *p*=0.007), lymphovascular invasion (HR=1.817; 95% CI: 1.086--3.041; *p*=0.023), and late TNM stage (HR = 2.886; 95% CI: 1.374--6.509; *p*=0.005) were statistically independent forecasting factors of adverse outcome for GC ([Tables 2](#t2-cmar-9-539){ref-type="table"} and [3](#t3-cmar-9-539){ref-type="table"}).

Discussion
==========

GC is a highly heterogeneous disease with poor clinical outcomes. The traditional stage classification systems have limited capacity to predict the results of GC patients. More relevant studies should be undertaken to refine prognosis, comprehend progression, and improve treatment. Investigations have showed that protein synthesis is central to the occurrence and development of tumors. Translational control occurs in any phase of protein synthesis, and it is believed that the initiation phase of translation plays an important role during the process.[@b23-cmar-9-539],[@b24-cmar-9-539] eIF3 is the largest and most intricate eIF, consisting of thirteen subunits. This polypeptide interacts with the 40S subunit of free-floating ribosomes and stabilizes the eIF2--GTP--Met--tRNAi complex.[@b6-cmar-9-539],[@b7-cmar-9-539] eIF3d is the largest subunit of eIF3 and its function may be crucial. Some studies showed that eIF3d was required for the stable association of eIF3 subunits.[@b14-cmar-9-539] Based on these observations, it may be inferred that eIF3d is essential in promoting protein synthesis in the occurrence of cancer through certain molecular mechanisms.

Previous studies have demonstrated that eIF3d was overexpressed in several human cancers, such as prostate cancer,[@b15-cmar-9-539] colon cancer,[@b16-cmar-9-539] and melanoma,[@b17-cmar-9-539] while also resistant to chemotherapy.[@b20-cmar-9-539] There have been recent studies on expression of other subunits of eIF3 in GC[@b9-cmar-9-539],[@b25-cmar-9-539]; however, the role of eIF3d in GC remains unclear.

In this study, immunohistochemical staining was used to evaluate the level of eIF3d in GC and to analyze with the resultant clinicopathology and prognosis. The data showed that eIF3d was remarkably higher in GC tissues than companion ANC tissues. In addition, eIF3d was positively correlated with the tumor stage, as determined by lymph node metastasis and depth of invasion. The Kaplan--Meier survival analysis showed that patients with high eIF3d expression had significantly poorer survival compared with patients with low eIF3d expression, particularly those in stage III. This was consistent with the result that eIF3d overexpression was more frequent in late-stage patients. Furthermore, multivariate Cox regression analyses showed that the level of eIF3d was an independent predictive factor of poor prognosis for GC as well as lymph node metastasis, serosa invasion, and lymphovascular invasion. Thus, eIF3d might serve as an efficient prognostic biomarker in GC.

In consideration of its indispensable role in protein synthesis and cell proliferation, eIF3d could be a potential target for gene therapy in GC. It was reported that knockdown of eIF3d could inhibit the growth of colon and breast cancer cells by inducing cell-cycle arrest at the G2/M phase or suppressing the Wnt/β-catenin signaling pathway.[@b16-cmar-9-539],[@b19-cmar-9-539] This study showed the relationship between eIF3d and the malignant behavior of GC at the immunohistochemical level implying that eIF3d may promote tumor growth. However, further studies should be performed at the cellular and molecular levels to reveal the underlying mechanism and should look for the possibility of making use of eIF3d in GC treatment.

Conclusion
==========

To our knowledge, this study represents a first report identifying that eIF3d was upregulated in GC. Elevated expression of eIF3d was an independent poor prognostic factor in GC. We suggest that eIF3d could be a good biomarker in GC.
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![The expression of eIF3d in gastric cancer tissues and adjacent noncancerous tissues.\
**Notes:** (**A**) High eIF3d expression in gastric cancer tissues. (**B**) Low eIF3d expression in gastric cancer tissues. (**C**) Negative eIF3d expression in adjacent noncancerous tissues. Magnification ×20.\
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![Kaplan--Meier analysis for overall survival of patients with gastric cancer according to eIF3d expression.\
**Notes:** (**A**) The overall survival in all patients. (**B**) The overall survival in patients with TNM I stage. (**C**) The overall survival in patients with TNM II stage. (**D**) The overall survival in patients with TNM III stage.\
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###### 

Relationship of eIF3d expression with clinicopathological parameters of tumor

  Clinical parameters           N     eIF3d expression   *p*-value   
  ----------------------------- ----- ------------------ ----------- --------------------------------------------------
  **Total**                     210   115 (54.8)         95 (45.2)   
  **Gender**                                                         0.239
   Male                         135   78 (57.8)          57 (42.2)   
   Female                       75    37 (49.3)          38 (50.7)   
  **Age, years**                                                     0.306
   \<60                         109   56 (51.4)          53 (48.6)   
   ≥60                          101   59 (58.4)          42 (41.6)   
  **Primary tumor location**                                         0.403
   Upper 1/3                    21    11 (52.4)          10 (47.6)   
   Middle 1/3                   49    29 (59.2)          20 (40.8)   
   Lower 1/3                    130   72 (55.4)          58 (44.6)   
   Multiple                     10    3 (30.0)           7 (70.0)    
  **Tumor differentiation**                                          0.052
   Well                         6     1 (20.0)           5 (80.0)    
   Moderate                     36    16 (44.4)          20 (55.6)   
   Poor                         168   98 (58.3)          70 (41.7)   
  **Tumor depth**                                                    0.004[\*](#tfn1-cmar-9-539){ref-type="table-fn"}
   T1/T2/T3                     123   77 (62.6)          45 (37.4)   
   T4 (serosa invasion)         87    38 (43.7)          50 (56.3)   
  **Lymph node metastasis**                                          0.041[\*](#tfn1-cmar-9-539){ref-type="table-fn"}
   Negative                     73    47 (64.4)          26 (35.6)   
   Positive                     137   68 (49.6)          69 (50.4)   
  **Distant metastasis**                                             0.502
   Negative                     205   113 (55.1)         92 (44.9)   
   Positive                     5     2 (40.0)           3 (60.0)    
  **TNM stage**                                                      0.304
   I                            65    41 (63.1)          24 (26.9)   
   II                           44    25 (56.8)          19 (43.2)   
   III                          96    47 (49.0)          49 (51.0)   
   IV                           5     2 (40.0)           3 (60.0)    
  **Early or late stage**                                            0.027[\*](#tfn1-cmar-9-539){ref-type="table-fn"}
   I/II                         106   66 (62.3)          40 (37.7)   
   III/V                        104   49 (47.1)          55 (52.9)   
  **Lymphovascular invasion**                                        0.974
   Negative                     166   91 (54.8)          75 (45.2)   
   Positive                     44    24 (54.5)          20 (45.5)   

**Note:**

*p*\<0.05: statistical significance.

**Abbreviation:** eIF3d, eukaryotic initiation factor 3 subunit d.

###### 

Univariate analysis of the correlation between clinicopathological parameters and survival time in patients with gastric cancer

  Clinical parameters       *p*-value
  ------------------------- ----------------------------------------------------
  Age                       0.052
  Gender                    0.620
  Lymphovascular invasion   \<0.001[\*](#tfn3-cmar-9-539){ref-type="table-fn"}
  eIF3d expression          0.006[\*](#tfn3-cmar-9-539){ref-type="table-fn"}
  Tumor differentiation     0.096
  Lymph node metastasis     \<0.001[\*](#tfn3-cmar-9-539){ref-type="table-fn"}
  Distant metastasis        \<0.001[\*](#tfn3-cmar-9-539){ref-type="table-fn"}
  Serosa invasion           \<0.001[\*](#tfn3-cmar-9-539){ref-type="table-fn"}

**Note:**

*p*\<0.05: statistical significance.

**Abbreviation:** eIF3d, eukaryotic initiation factor 3 subunit d.

###### 

Multivariate analysis of the correlation between clinicopathological parameters and survival time in patients with gastric cancer

  Clinical parameters       B       SE      Wald     *df*   *p*-value                                          HR      95% CI
  ------------------------- ------- ------- -------- ------ -------------------------------------------------- ------- --------------
  Age                       0.081   0.242   0.113    1      0.737                                              0.922   0.574--1.481
  Gender                    0.029   0.264   0.012    1      0.911                                              0.971   0.579--1.627
  Lymphovascular invasion   0.569   0.267   4.541    1      0.033[\*](#tfn6-cmar-9-539){ref-type="table-fn"}   0.566   0.336--0.955
  eIF3d expression          0.545   0.248   4.836    1      0.028[\*](#tfn6-cmar-9-539){ref-type="table-fn"}   0.580   0.357--0.942
  Tumor differentiation     0.651   0.354   3.372    1      0.066                                              0.522   0.261--1.045
  Lymph node metastasis     1.545   0.457   11.442   1      0.001[\*](#tfn6-cmar-9-539){ref-type="table-fn"}   0.213   0.087--0.522
  Distant metastasis        1.688   0.515   10.731   1      0.001[\*](#tfn6-cmar-9-539){ref-type="table-fn"}   0.185   0.067--0.508
  Serosa invasion           0.735   0.284   6.692    1      0.010[\*](#tfn6-cmar-9-539){ref-type="table-fn"}   0.480   0.275--0.837

**Notes:** B: Regression coefficient estimate, Wald: used for checking the B value.

*p*\<0.05: statistical significance.

**Abbreviations:** eIF3d, eukaryotic initiation factor 3 subunit d; SE, Standard error; *df*, degrees of freedom; HR, hazard ratio; CI, confidence interval.
